MedTrace Logo

Treatment of Depression in Adults

NCT00073697 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 290

Last updated 2012-01-11

No results posted yet for this study

Summary

This study will determine how certain features of depressed individuals affect their responses to depression treatment.

Conditions

Interventions

DRUG

Escitalopram

Participants will receive escitalopram for a minimum of 32 weeks or approximately 8 months. Participants whose symptoms become stabilized will continue the initial treatment for another 6 months.

BEHAVIORAL

Interpersonal Psychotherapy

Participants will receive interpersonal psychotherapy (IPT) for 8 months and possibly an additional 6 months.

OTHER

Escitalopram plus IPT

Participants whose symptoms become stabilized will continue the initial treatment for another 6 months. Those who do not will have the second treatment added to their regimen until remission occurs.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Ellen Frank · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
66 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • United States
  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00073697 on ClinicalTrials.gov